ALSAF Stock Overview
A medical technology company, engages in the design, manufacturing, and marketing of sterile implants and single-use sterile surgical instruments for the treatment of spinal surgery. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Safe Orthopaedics SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.09 |
| 52 Week High | €72.00 |
| 52 Week Low | €0.071 |
| Beta | 0 |
| 11 Month Change | -72.33% |
| 3 Month Change | -85.02% |
| 1 Year Change | -99.83% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| ALSAF | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | -24.4% | 2.7% | -0.3% |
| 1Y | -99.8% | 26.7% | -3.5% |
Return vs Industry: ALSAF underperformed the French Medical Equipment industry which returned 28.4% over the past year.
Return vs Market: ALSAF underperformed the French Market which returned -2.5% over the past year.
Price Volatility
| ALSAF volatility | |
|---|---|
| ALSAF Average Weekly Movement | 44.6% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALSAF's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALSAF's weekly volatility has decreased from 64% to 45% over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 138 | Nicolas Papillon | www.safeorthopaedics.com |
Safe Orthopaedics SA, a medical technology company, engages in the design, manufacturing, and marketing of sterile implants and single-use sterile surgical instruments for the treatment of spinal surgery. The company’s products portfolio includes SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies, as well as essential kit for percutaneous treatment of spinal fractures; SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems; SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. Safe Orthopaedics SA was founded in 2010 and is headquartered in Eragny-sur-Oise, France.
Safe Orthopaedics SA Fundamentals Summary
| ALSAF fundamental statistics | |
|---|---|
| Market cap | €335.00 |
| Earnings (TTM) | -€205.44m |
| Revenue (TTM) | €5.81m |
0.0x
P/S Ratio0.0x
P/E RatioIs ALSAF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALSAF income statement (TTM) | |
|---|---|
| Revenue | €5.81m |
| Cost of Revenue | €1.49m |
| Gross Profit | €4.32m |
| Other Expenses | €209.77m |
| Earnings | -€205.44m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -55.02k |
| Gross Margin | 74.41% |
| Net Profit Margin | -3,536.04% |
| Debt/Equity Ratio | -133.2% |
How did ALSAF perform over the long term?
See historical performance and comparison